Skip to main content

Want a detailed portfolio tracker?

Performance analysis of NLS Pharmaceutics (NCEL)

Annual Return

Over the past 3 years, NCEL has had an average annual return of -77.59%, underperforming the benchmark SPY, which returned +19.31% annual.

Over the past 5 years, NCEL has had an average annual return of -68.09%, underperforming the benchmark SPY, which returned +12.55% annual.

Since Jan 29, 2021, NCEL has had an average annual return of -64.60%, underperforming the benchmark SPY, which returned +15.11% annual.

202620252024202320222021
+112.50%-91.26%-91.03%-54.28%+16.22%-61.59%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+37.50%+13.64%-28.00%+111.11%-21.05%+6.67%+6.25%+112.50%
2025+17.49%-26.05%-16.35%-4.51%+49.61%+32.11%-36.65%+15.09%-13.66%-60.13%-44.44%-54.29%-91.26%
2024-22.00%-15.95%-53.44%-22.47%+1.04%+53.89%+1.07%-32.02%-14.92%-28.47%-7.01%-37.33%-91.03%
2023+0.76%+10%+6.31%-12.51%-20.30%+3.76%-15.66%+9.94%-31.37%-5.70%-36.38%+40.47%-54.28%
2022-18.93%+32.24%+18.48%-39.21%-20.67%-13.64%-37.01%+33.75%+25.29%-15.71%+58.85%+55.43%+16.22%
2021+0%-1.04%+41.26%-9.41%-5.73%-8.99%-17.19%-5.00%+1.22%-13.61%-6.02%-45.32%-61.59%

Drawdown analysis of NLS Pharmaceutics (NCEL)

The maximum drawdown for the NCEL was -99.92%, occurring on Dec 31, 2025. This drawdown has not yet recovered.

The current NCEL drawdown is -99.83%.

Since Jan 29, 2021 NCEL has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 2 times
  • 20% or more: 2 times
  • 10% or more: 2 times
DepthStartTo BottomBottomTo RecoverEndTotal
-99.92%Mar 12, 20211207Dec 31, 2025OngoingOngoingOngoing
-35.42%Feb 11, 202115Mar 5, 20215Mar 12, 202120
-9.34%Jan 29, 20211Feb 1, 20212Feb 3, 20213
-7.69%Feb 4, 20212Feb 8, 20213Feb 11, 20215